Home/Pipeline/ADB-104

ADB-104

Epilepsy

Pre-clinicalActive

Key Facts

Indication

Epilepsy

Phase

Pre-clinical

Status

Active

Company

Adolore BioTherapeutics

About Adolore BioTherapeutics

Adolore BioTherapeutics is developing a novel neuromodulation platform centered on a proprietary gene therapy that delivers a novel CA8 therapeutic peptide directly inside targeted neurons and nerve fibers. Their lead programs target chronic osteoarthritis knee pain and the rare condition erythromelalgia, with a broader pipeline extending into epilepsy, hearing loss, and ophthalmology. The company's mission is to create safe, effective, and accessible non-opioid therapies to combat the opioid crisis by providing highly localized, disease-modifying treatments.

View full company profile

Therapeutic Areas

Neurology Pain Management Rare Disease Ophthalmology Audiology

Other Epilepsy Drugs

Drug	Company	Phase	Status
ADX71149 (mGlu2 PAM)	Addex Therapeutics	Phase 2	Active (with Janssen)
TRV045	Trevena	Phase 1	Active
SAGE-324	Sage Therapeutics	Preclinical	Research
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
Not Publicly Disclosed	Cerecin	Phase 2	Active
eTNS Platform	NeuroSigma	Unknown	Active
NPT 2042	NeuroPro Therapeutics	Phase 2	Active
Spritam (levetiracetam)	Aprecia Pharmaceuticals	Approved	Active
Perampanel	Ark Diagnostics	In Development	Active
NeuroAccess Platform	Cordance Medical	Pre-clinical/Research	Active
Epilepsy Program	Current Surgical	Research	Active
GABA-A PAM for Epilepsy	Modulate Bio	Preclinical	Active